Single-use technology for solvent/detergent virus inactivation of industrial plasma products

Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products

(2014) W.A. Germishuizen et al.   BIOLOGICALS

Virus elimination during the purification of monoclonal antibodies by column chromatography and additional steps

(2014) Peter L. Roberts   BIOTECHNOLOGY PROGRESS

Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectablein vitrothrombogenic activity

(2014) M. Vargas et al.   VOX SANGUINIS

Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG

(2013) Yu-Wen Wu et al.   TRANSFUSION

Viral Safety of Human Plasma–Derived Medicinal Products: Impact of Regulation Requirements

(2013) Karin J. Velthove et al.   TRANSFUSION MEDICINE REVIEWS

Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation

(2012) Peter L. Roberts et al.   BIOLOGICALS

Chikungunya virus and the safety of plasma products

(2012) Sandra M. Leydold et al.   TRANSFUSION

Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies

(2009) Herbert O. Dichtelmüller et al.   TRANSFUSION

Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system

(2009) M. El-Ekiaby et al.   TRANSFUSION MEDICINE

Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance

(2009) M. Radosevich et al.   VOX SANGUINIS